UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume - Still a Buy?

Key Points

• UCB SA's stock saw an impressive 772% increase in trading volume, with 7,729 shares exchanged compared to just 886 shares in the previous session.
• Morgan Stanley has upgraded UCB shares to an "overweight" rating, reflecting positive sentiment among Wall Street analysts.
• The stock is currently trading at $213.80, having previously closed at $219.79, with its 50-day and 200-day moving averages at $195.22 and $184.13 respectively.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 7,729 shares changed hands during mid-day trading, an increase of 772% from the previous session's volume of 886 shares.The stock last traded at $213.80 and had previously closed at $219.79.

Analysts Set New Price Targets

Separately, Morgan Stanley raised UCB to an "overweight" rating in a report on Monday, June 23rd.

UCB Stock Performance

The stock has a 50 day simple moving average of $197.49 and a 200 day simple moving average of $184.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.